Abstract The common paradigm for conceptualizing the influence of genetic and environmental factors on a particular disease relies on the concept of risk. Consequently, the bulk of etiologic, including genetic, work focuses on Briskf actors. These factors are aggregated at the high end of the distribution of liability to disease, the latent variable underlying the distribution of probability and severity of a disorder. However, liability has a symmetric but distinct aspect to risk, resistance to disorder. Resistance factors, aggregated at the low end of the liability distribution and supporting health and recovery, appear to be more promising for effective prevention and intervention. Herein, we discuss existing work on resistance factors, highlighting those with known genetic influences. We examine the utility of incorporating resistance genetics in prevention and intervention trials and compare the statistical power of a series of ascertainment schemes to develop a general framework for examining resistance outcomes in genetically informative designs. We find that an approach that samples individuals discordant on measured liability, a low-risk design, is the most feasible design and yields power equivalent to or higher than commonly used designs for detecting resistance genetic and environmental effects.
The bulk of research into the human condition has focused on disease, disorder, or infection. Accordingly, guided by the medical priority of dealing with disease, it is the factors that increase the probability and severity of the disorder, i.e., Brisk^factors, that are pursued in biomedical studies. These factors include environmental (e.g., infectious agents) and genetic (mutations and riskassociated alleles of genetic polymorphisms). Given the obvious success in identifying risk/causal factors for Bsimple^diseases (e.g., infections; Mendelian or singlegene disorders), researchers have consequently carried these approaches to the study of complex (multifactorial) disorders. It should be noted, however, that success in translation of findings even in Mendelian disorders has been low, as the strong genetic effects are difficult to compensate for or correct. For much more common complex disorders, the detection of single genetic effects is difficult because of their small impact: many genes contribute to individual differences in the risk, and that number is further augmented by the genetic and phenotypic (observed trait) heterogeneity of the disorder. As a rule, that implies the necessity of extremely large sample for such effects' detection, while compensating for them may be both difficult and ineffective.
Importantly, risk for a disorder is one aspect of liability, a latent trait comprising effects of all factors influencing an individual's probability of developing a disorder and its severity (Falconer 1965) . Hence, variation in liability to a complex disorder is due to individual differences in a large number of genetic and environmental influences. According to the liability-threshold model, whereby affected phenotypes are generally above a certain threshold point on the liability scale, higher values on the liability continuum correspond to higher risk for disease and increased severity (REICH et al. 1972) .
Vanyukov et al. (Vanyukov et al. 2016 ) present the concept of resistance as the aspect of liability that is symmetric to risk (Fig. 1) . Accordingly, resistance factors are defined as those decreasing the probability and severity of a disorder. Work on resistance to disease has until now largely been limited to one of its facets, resilience. Resilience is conceptualized as Bsuccessful^adaptation after exposure to adversity (Luthar et al. 2000; Masten 2001 ) and is thus contingent on the latter. Reviewed elsewhere (Cicchetti 2010) , adoption of a resilience perspective has allowed investigators to recast research on outcomes of high-risk populations, from the deterministic impact of the environment to individual differences in response to the environment. While this is valuable, resilience captures only the organism's dynamic response, or adaptation, to a stressor rather than the complete nature of disease risk, including that outside of the context of a particular exposure or exposure response. Resilience is also commonly inferred post hoc upon observation of Bsuccessful^adaptation to a presumed stressor (Bsocial disadvantage or highly adverse conditions ( Windle 2002) , rather than being a disorder-specific measurable construct. Unsurprisingly, the genetic studies of resilience (Feder et al. 2009 ) are in effect studies of stress response mechanisms rather than resilience as a trait. The examples of findings reviewed by Feder and colleagues (Feder et al. 2009 ) are largely if not exclusively related to risk and disease (psychopathology) rather than lack thereof, which would be indicative of resistance (and potentially resilience). Adversity causing stress is also only one characteristic of the environment that potentially contributes to disorder liabilities.
While resilience has garnered a fair amount of attention, the broader concept of resistance has only recently been discussed (Vanyukov et al. 2016) as the preferred and necessary alternative to the Brisk^perspective. Resistance factors are not limited to the individual's ability to rebound from or adapt to stressors (corresponding to resilience) and to the opposites of respective risk factors (usually described as Bprotective factors^) but also include factors that limit exposure to risk increasing environments and response to stressors or pathogens (e.g., drugs), increase exposure and sensitivity to environments which decrease risk, as well as enable absence of relapse upon recovery. Whereas risk factors are expected to be aggregated among the affected and other Bhigh-risk^individ-uals, resistance factors are likely to be aggregated among high-resistance individuals, representing the opposite end of the liability distribution (Fig. 1) .
Nevertheless, research has been focused on risk factors and high-risk sampling, which largely relies on oversampling affected cases or individuals expected to be at a high risk for a particular disorder. One reason for that is the belief that, akin to some infectious diseases, like tuberculosis, once the risk/etiological factor is identified, it can be removed. Another possible reason is the difficulty in selecting a priori low-risk samples: there are usually no overt face-valid indicators of high resistance that are comparable to the common indicators of high risk, the symptoms and the categorical diagnosis of the disorder. Whereas the low liability to a Mendelian disorder can be relatively readily ascertained (virtually anybody from the general population, if unaffected, is likely to have no/low risk), the same approach cannot be applied to multifactorial liabilities. When an allele is defined as Bprotective^in genetic association studies, it is usually by virtue of being alternative to the Brisk^allele. However, such alternatives of risk factors, genetic and non-genetic, derived from the control samples representing ∼90-95 % of the population-are likely to be of an average/neutral rather than a high-resistance effect (Vanyukov et al. 2016) . The rare exceptions resulting in such an effect (e.g., the low activity ALDH2 allele for alcoholism, and smallpox vaccine) have historically been discovered due to the inadvertent selection of a highresistance sample.
Genetics presents a telling example of the asymmetry of the Brisk^approach. One of the once most popular association tests, the transmission-disequilibrium test (TDT), deals with alleles that are Bovertransmitted^from heterozygous parents to the affected offspring. Not only are the unaffected offspring not studied, but the Bundertransmittedâ lleles are disregarded-obviously because they are not Brisk^alleles. Regrettably, such family-based studies were even proposed to be the only type of genetic association research acceptable for publication consideration, with case-control research rejected in its entirety (Paterson 1997) , preceding the ascendance of whole genome scans, which are largely case-control studies ill-powered to detect resistance factors. As currently construed, however, neither genetic case-control nor family-based studies target resistance factors and enable their efficient detection. Below, we discuss application of the case-control design to introduce changes needed to reorient research from risk to resistance. We focus initially on genetic resistance factors in addiction, where significant successes have been realized, and extend that to other cases. 
Addiction
Investigations of the impact of measured genetic (i.e., DNA polymorphisms) influences on variation in the liability to drug addiction, in common with other complex disorders, have had limited success in explaining its total heritability, the proportion of the trait's variance that is due to genetic factors. Replicable findings of a meaningful effect of genetic variants on disease risk or trajectory in drug addiction have been few (Bierut 2011; Hartz and Bierut 2010; Maher et al. 2011; Treutlein and Rietschel 2011) , both for specific drugs (Tobacco and Genetics Consortium 2010; Xie et al. 2011) as well as for general liability to addiction (Maher et al. 2011; Schwantes-An et al. 2015) .
As noted above, case-control designs focus on identifying factors for increased disease risk and increase power to identify risk factors by oversampling cases and consequently enriching the sample for Brisk^factors. Early genetic studies of addiction frequently contrasted drug-dependent cases and age/sex matched unaffected population controls. However, pathogenesis of substance use disorder (SUD) is a multistage process, progressing first through drug use, then abuse, and ultimately psychological and physiological dependence and compulsive pursuit of drugs (addiction), with varying influence of genes and environment on individual variation by stage. Including controls who have not ever used drugs hinders focusing on a specific stage of dependence. Study designs that use controls who report drug exposure but do not satisfy criteria for SUD (addiction) likely deliver greater power to detect allelic associations pertaining to risk for dependence, since it is unclear if controls who have never used would develop dependence if exposure occurred. Consistent with this observation, the recent successes in addiction genetics have been in studies focusing on variation within drugexposed populations or included controls with significant exposure (Cornelis et al. 2011; Sulem et al. 2011; Tobacco and Genetics Consortium 2010) . In genetic studies of tobacco addiction (e.g., (Saccone et al. 2007 ; Tobacco and Genetics Consortium 2010), the importance of using screened controls is highlighted. Using a very large sample (N = 143,023), Tobacco and Genetics Consortium researchers performed a genome-wide association scan or tests of association between approximately one million SNPs genome-wide, and phenotypes of smoking including age of initiation, use and cessation, with minimal success. In a smaller sample restricted to smokers (N = 73,853) for smoking quantity, a highly significant association of characteristics of smoking with the nicotinic acetylcholine receptor gene cluster (CHRNA5-A3-B4) on chromosome 15 was replicated. In prior studies, similar results had been found using controls who were limited to smokers who had not become dependent (Saccone et al. 2010) . It is believed that specific variants in these loci confer elevated risk to nicotine dependence after commencing smoking via differences in corticostriatal response to nicotine (Janes et al. 2012) .
It is noteworthy that it is risk for, rather than resistance to, the development of dependence that has been targeted in most research. Resistance-enhancing effects, if any reported, are either defined by an allele's virtue of being the alternative to the Brisk^allele, or noted inadvertently, as, for instance, the detection of the Bprotective^effect of the minor allele of the rs16969968 SNP of the CHRNA5 gene (a Brisk^allele for nicotine dependence) on the risk for cocaine dependence (Grucza et al. 2008 ). The largest addiction-related genetic effect, however, has been established when a phenotypic resistance factor was specifically targeted. A higher sensitivity to ethanol (Bflushing^upon exposure) among East Asians (particularly, the Japanese) was established by comparison with Caucasians (Wolff 1972 ) and subsequently experimentally related to a higher level of acetaldehyde upon exposure to ethanol (Wolff 1973) . Flushing among the Japanese was then related to the Batypical^form of acetaldehyde dehydrogenase deficiency (Harada et al. 1981) and, finally, to the ALDH2*2 allele of the gene coding for the β2 subunit of the enzyme (Goedde et al. 1983) . Variants in genes involved in alcohol metabolism leading to increases in acetaldehyde either through the increased oxidation of alcohol to acetaldehyde (ADH1B) or through slowing the rate of conversion of acetaldehyde to acetate (ALDH2) have been associated with quantitative differences in alcohol consumption (Crabb et al. 1989; Luczak et al. 2006; Peng and Yin 2009) . Obviously, these resistance genetic effects are discoverable only in samples examining use variation in those who have tried drinking. Consequently, the use of exposed controls has become a more common approach in substance abuse genetics. It should be noted, however, that while exposed controls facilitate the detection of factors related to elevated risk for physical dependence, the factors-including genetic ones-that lower the probability of drug exposure and thus enhance resistance are undetectable with this sampling scheme. To a large degree, the same pertains to the factors that influence the magnitude of exposure (usually limited to a substantial but relatively low number of drug experiences).
Other Diseases
The recent explosion of genomic data has allowed systematic searches for Bfairy godmother^mutations or genetic variants that confer disease resistance (Williams 2016) . For example, recent work screened genomic sequence data from >589,000 subjects to identify 13 subjects with Mendelian disease causing mutations but without apparent disease. Other work has concluded that roughly 5 % of healthy adults carry mutations predicted to Bcause^disease (Johnston et al. 2015) but that screening of cohorts is vastly underpowered to detect specific protective factors, whether genetic or environmental. Hence, investigators focused on specific diseases or mechanisms have relied on several different, and frequently ad hoc, approaches to identify resistance variants.
The usual approach to discovering protective variants has been to focus on those thought to be at risk but without disease. This approach has been frequently applied to infectious disease, where exposure risk is known. Possibly most notable, a specific variant in CCR5, the gene encoding for an HIV co-receptor for binding and entry into CD4+ T cells called the CC-chemokine receptor 5, confers resistance to HIV infection. The 32 base pair deletion, CCRdelta32, results in a nonfunctioning CCR5 and confers immunity to HIV to those homozygous for the m u t a t i o n (D e a n e t a l . 1 996 ; Liu et al. 19 96 ) . Importantly, identifying these variants relied on the study of highly exposed controls. Utilizing a novel study design, focusing on HIV-seropositive subjects with and without tuberculosis from high TB exposure regions, Sobota and colleagues (Sobota et al. 2016 ) successfully identified a TB resistance variant in a histone mark on chromosome 5 near IL12B. Other work using exposed controls has identified, or is aiming to identify, resistance variants for other infectious diseases, including influenza (Hsu and Spindler 2012) , malaria (Shelton et al. 2015) , Kuru (Mead et al. 2009 ), and other prion diseases (Asante et al. 2015) .
The concept of biological resistance exists and has relevance beyond infectious disease and addiction; however, identification of those Bat risk^may often be less discrete than having been exposed to an infectious pathogen or addictive substance and instead rely on ad hoc definitions of liability. Freudenberg-Hua (Freudenberg-Hua et al. 2014) focused on whole genome sequencing of 44 centenarians with known common disease risk factors (e.g., obesity, smoking) but who were healthy in a quest to identify disease-protective variants. The study of overweight individuals without Type 2 Diabetes successfully identified resistance variants in SLC30A8 (Flannick et al. 2014) . In a study of 500 Ashkenazi Jews over 95 years old, adinopectin resistance mutations, protective against arterial inflammation, and resistance mutations in the cholesterylester transfer protein gene, protective against high cholesterol and consequent health outcomes, were identified (Barzilai and Gabriely 2010; Schechter et al. 2010) . Not all investigations of genetic resistance in subjects at-risk for but without disease have yielded similar successes. For example, recently a genome sequencing study of 454 Bwellderly^subjects over 80 with no chronic disease failed to identify protective variants (Erikson et al. 2016 ). Thus, a framework for investigating genetic resistance is needed to avoid further reliance on serendipitous discovery or secondary analyses in samples not ascertained to study resistance. The need for innovative study design is more pronounced in prevention trials, where the use of random samples of hundreds of thousands of subjects to identify tens of resistant subjects is infeasible.
The goal of this work is to explore the power of a range of study designs to discover novel genetic and environmental resistance factors. Those study designs include case-control, representative sampling, a low risk-design, and the high-risk design. We also examine modifications of the high-risk design, an approach where subjects are selected based on the presence of a phenotype of interest in a parent. The intent of the high-risk design is to enrich for Brisk^factors, both genetic and family environment, to increase the probability of disease outcomes in the offspring. We treat the case-control design as the reference approach, since it is the most widely used approach to over-ascertainment of cases relative to population prevalence in order to gain power. For resistance studies, we explore whether sampling based on environmental exposures and parental phenotype impacts the power to detect specific genetic and environmental resistance factors. We use a simulation-based approach and assume an underlying continuous disease liability to compare the power to detect novel resistance factors under each study design.
Materials and Methods
In this section we describe (1) the study designs aimed at detecting resistance factors; (2) the multifactorial liability threshold model used to generate disease status; and (3) the approach to data simulation we used.
Study Designs
We compared the power of six different study designs to detect resistance effects for a dichotomous outcome by simulation (Fig. 2) . Our intent is to mimic sampling strategies that could be used in a typical intervention or prevention trial, with subjects ascertained prior to onset of the outcome and assume a sampling unit of a parent-child trio. We treated a case-control sampling strategy as the reference group (Fig. 2a) with a sample of 500 trios with an affected offspring and 500 control trios, irrespective of parental affection status. We examined random sampling of 1,000 trios from the population (Fig. 2b) , where trios where simulated as randomly ascertained from the population with respect to all parameters. We included a low-risk (high resistance) design (Fig. 2c) . Under the low-risk design, a sample of 1,000 offspring from a larger total population is selected from below the 10th percentile and above the 60th percentile respectively on a known liability distribution. We examined the power of the high-risk design, where subjects were ascertained through the father, with 500 case fathers and 500 control fathers (Fig. 2d) . We also examined two modifications of the high risk design, both of which included sampling conditional on a single measured continuous environmental factor which accounted for 25 % of the total variance in the underlying liability. Under the low environmental risk sampling approach (Fig. 2e) , 500 highrisk (case father) and 500 low-risk (control father) trios were selected from the bottom half of the measured environmental risk scale. Under the extreme environmental sampling approach, 500 high-risk (affected father) trios were selected with values on the environmental risk below the mean and 500 low-risk (control father) trios were selected with environmental risk above the mean (Fig. 2f) .
Disease Model
We assumed a liability threshold model, where an underlying continuous risk trait captures all genetic and environmental contributions to risk and resistance. Under this model and for this work, this is operationalized as
where Z i is the liability trait, β 1 is the correlation between polygenic risk X 1 and outcome (assuming standardized coefficients), β 2 is the correlation between family environment X 2 and outcome, β 3 is the correlation between a specific SNP genotype X 3 and outcome, β 4 is the correlation between a specific protective environment X 4 and outcome, and ε is the residual variance. Outcomes were dichotomized to a disease outcome (Y i ) by
Simulation
Samples of trios were directly simulated via Monte Carlo simulation. First mother and father polygenic risk, family environmental risk, and individual protective environment were simulated from a standard normal distribution. A single resistance SNP was simulated in parents. Genetic variables were simulated in the offspring conditional on parental SNPs using gene-dropping simulation and on parental polygenic risk as the mean of parental polygenic risk. Given a set of correlations and residual variance, a random normal (0, 1) underlying risk was directly simulated per individual. Risk was dichotomized to disease status via the logit model with a constant added to simulate a specified population prevalence of disorder. In all simulations, we assumed a population prevalence of 5 %. For the case-control and high-risk design samples we oversimulated to generate 500 case or high-risk families from the stated environmental quantiles, respectively. In the low-risk design, we over-simulated to generate 500 subjects with liability at or below the 10th percentile and 500 subjects above the 60th percentile. In the random design, we simulated 1,000 trios irrespective of outcome and environmental stratum. We selected parameter values for genetic and environmental effects similar to those seen for common behavioral outcomes. However, since the goal of this work is to examine the comparative power of these approaches, the values of the parameters is not of critical importance since the relative power of the approaches is unlikely to change under different effect sizes. We assumed a minor allele frequency of the protective allele of 0.3, an overall trait heritability of 0.50, the variance accounted for by the family environment of 0.25. We varied the impact of the protective SNP and individual environment. For each of 1,000 iterations under each study design, we tested the association between the offspring protective SNP and protective individual environment with outcome via logistic regression. Power was calculated at α = 0.05 or the proportion of Monte Carlo replicates that yielded a p value less than .05.
Results
The results are presented in Table 1 corresponding directly to the models in Fig. 2 . The impact of the protective environment was varied at R 2 of 0.0225, 0.04, and 0.0625. The effect of the protective allele was varied at effect sizes, indexed as deviation from the heterozygote mean of −0.15, −0.20, and −0.25, yielding an additive genetic variance of 0.009, 0.017, and 0.026 respectively at a minor (protective) allele frequency of .3. Power is presented at an alpha of .05. It is important to note that relative, and not absolute, power is of interest in comparative analyses such as this. It is expected that any factors which would increase or decrease power, such as change in effect size or sample size, would similarly affect the power of all approaches. As expected, case-control sampling yields substantial improvements over random sampling for detecting protective SNP and environment effects across all effect sizes. The low risk design, where subjects are ascertained at a low liability, yields power equivalent to a case-control design to detect SNP effects and much higher power to detect the protective environmental effect. The high-risk design yields power increases similar to case-control sampling with the exception of at smaller SNP effect sizes, where the high-risk design performs better. This is most likely due to an enrichment in SNP effects in high-risk families with control offspring. Sampling with a high-risk design from an environmental risk below the mean yields a power profile similar to a case-control design. Sampling high-risk families from below the population mean in environmental risk and low-risk families from above the population mean yields dramatic increases in power across the range of effects to detect both protective SNP and environmental effects.
Discussion
Since the advent of the genome-wide era, the approach has been plagued by the multiple testing problem, something that was actually recognized before most genome-wide analyses were performed (Zaykin and Zhivotovsky 2005) . Realistic effect sizes may not stand out among a sea of 1 million tests. The problem of separating the genomic wheat from the chaff has led many to question the value of large-scale testing. Prevention trials are faced with an additional difficulty in that sampling occurs prior to the onset of disorder or the transition of interest. We performed simulation under a range of effect sizes. While the selection of sample and effect sizes to represent real world settings is important, we present power of the Resistance allele frequency = 0.3, heritability of outcome = 0.5, common environmental variance = 0.25 approaches for comparative purposes. That is, while the absolute power of a given sample size at a given effect is interesting, we are interested here only in the relative power of the designs and expect that the relative power of the designs will remain constant across sample size and effect size. We demonstrated that sampling approaches that increase the proportion of resistant cases versus random sampling or casecontrol sampling lead to increases in the power to detect resistance effects. The high-risk design, and modified approaches, yield power similar to, or much greater than, case-control sampling by increasing the presence and variability of factors that impact the liability distribution. Notably, a sampling approach that ascertains case and control fathers from below and above the mean on an environmental risk factor respectively yields dramatic increases in power to detect resistance factors. However, this approach, which is contingent both on parental phenotype and measured parental environment would rely on a much larger sample from which sub-sampling would occur, thus substantially limiting its feasibility. The obvious exception to this is extant cohorts with parental data. More importantly, the low-risk design which ascertains based solely on measured liability irrespective of parental phenotype, and is hence much more feasible, yields increases in power similar to the high-risk designs with the previously mentioned exception of extreme environmental risk sampling. We contend that the low-risk design is substantially more feasible and similar to sampling approaches that have been used with success in complex disease genetics for more than a decade (Risch and Zhang 1995; Risch and Zhang 1996) .
Successful implementation of the low-risk design, the most powerful approach that is not contingent upon parental phenotypes or the presence/absence of a particular outcome (the usual scenario in prevention trials), presents several barriers which are easy to overcome. The first is the establishment of common measures of resistance. An important way of defining a high-resistance phenotype is via developing a continuous index of liability to the disorder and selecting individuals from the low end of the distribution. Such an index, for instance, has been developed for measurement liability to drug addiction in children, before any exposure to drugs (Vanyukov et al. 2003a, b; Vanyukov et al. 2009; Vanyukov et al. 2016) . A second related barrier is the development and use of items, scales, and constructs that measure not just the Bbad^but also the Bgood.^A vestige of the disease era of research is the widespread existence of items, test, and scales designed to measure only a small part of the liability distribution, usually most informative around the threshold between Bnormal^and Bdisease.^The recent movement to researching Bdomains^is an important step in the direction of observing the full range of liability, at one end capturing those at high risk for affection with disease or in the disease spectrum, and at the other, those with high-resistance phenotypes. Similarly, polygenic approaches, which index tens, hundreds, or thousands of SNPs to create composite indices of genetic risk, have been developed (Maher 2015) and it is worthwhile to consider those as part of multifactorial resistance in the same way that polygenic risk scores are used in the context of multifactorial risk. To fully inform research on resistance, an integration of biology, context and their interplay is essential. As described by Falconer, liability is a latent trait comprising effects of all factors, genetic and environmental, influencing an individual's probability of developing a disorder (Falconer 1965) . Hence, scales developed to measure liability for sampling into prevention trials should comprise not only measures of phenotypic precursors but also genetic and environmental factors known to impact liability variation for studied outcomes.
While risk and resistance are symmetric liability aspects, resistance factors are not necessarily the opposites or alternative variants of the risk factors. This differentiates resistance from a more narrow concept of protective factors, which are Bopposite ends of the same continuum [as risk factors]^or, alternatively, moderate, mediate or buffer the effects of risk factors (Hawkins et al. 1992) . Aggregation, and thus the probability of detection, of risk and resistance factors differ in different portions of the liability distribution (Fig. 1) . These sets of factors are likely to partially overlap. An example could be a SNP allele conferring elevated risk and the alternative allele that may confer enhanced resistance. The alternative allele, however, may be neutral, i.e., of no discernible phenotypic effect on the background of all other factors, rather than protective. Analogously, a resistance-enhancing variant may exist and be detectable within high-resistance populations, while the alternative variant(s) is neutral, e.g., the ALDH2*2 allele (Goedde et al. 1983; Harada et al. 1981 ). The rest of ALDH2 variation only weakly, if at all, influences alcoholism risk (Macgregor et al. 2009 ). The distinction between the risk and resistance perspectives is nontrivial also because it entails differences in approaches to the identification of respective factors. Research that is focused on risk factors alone is likely to detect those with the strongest risk-increasing effects, aggregated, e.g., among the affected individuals, representing the high end of the liability distribution (5-10 % of the population). In contrast, phenotypes carrying strongest resistanceincreasing effects-genetic or environmental-are diluted by the heterogeneity of the typical unaffected control, sampled from 90 to 95 % of the population. Symmetric to high-risk groups, factors conferring high resistance are aggregated among those with phenotypes at the low end of the liability scale, requiring high-resistance sampling for their detection.
Factors enhancing resistance may have the highest translational impact. The smallpox vaccine is an example. It was developed before the main risk factor, the variola virus, was discovered, and vaccine production does not even involve this virus. The immune milkmaids, inoculated with cowpox, were the high-resistance population in the discovery of the smallpox vaccine. This example shows that resistance factors are not merely opposite to risk factors, and that extending the action of a resistance factor to the rest of the population may be more practicable than the removal of a risk factor. The most effective measures for HIV/AIDS prevention -condom use and abstention from risky sex or, for injection drug users, from needle-sharing -are also not specific to HIV but increase resistance to infection. Dealing directly with the Bpathogenî s appropriate in some cases (e.g., antiretroviral therapy for HIV; antibiotics for bacteria). Such an approach may be infeasible or ineffective in many other cases, while raising resistance to the pathogen may be more promising.
Researchers can use our findings in two clear ways: first, to guide etiologic research to enhance the likelihood of discovering resistance factors; second, our results can guide the modification of existing approaches to prevention and intervention research, to enhance our ability to identify factors that increase resistance to disease among apparently Bat-risk^subjects. Importantly, inclusion of resistant subjects in a randomized trial will limit the apparent effectiveness of the intervention unless those resistance factors are known and properly accounted for in the design.
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